Quick Answer
Verrica Pharmaceuticals Inc. reported Total Assets of $47.13 million for the year ending 2025.
- Verrica Pharmaceuticals Inc. showed a decrease of -12.9% in Total Assets from 2024 to 2025.
- This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $104.72 million | Q3 2018: $98.81 million | Q1 2019: $85.98 million | Q2 2019: $81.25 million | Q3 2019: $76.07 million | Q1 2020: $94.44 million | Q2 2020: $87.24 million | Q3 2020: $79.94 million | Q1 2021: $108.10 million | Q2 2021: $99.03 million | Q3 2021: $88.76 million | Q1 2022: $71.62 million | Q2 2022: $63.44 million | Q3 2022: $49.15 million | Q1 2023: $68.64 million | Q2 2023: $62.20 million | Q3 2023: $97.15 million | Q1 2024: $66.31 million | Q2 2024: $52.01 million | Q3 2024: $32.93 million | Q1 2025: $42.18 million | Q2 2025: $39.11 million | Q3 2025: $40.90 million.
- Over the full 9 years of available data (2017 to 2025), Verrica Pharmaceuticals Inc.'s Total Assets has grown by 418.9%.
- Historical annual values: Fiscal year 2025: $47.13 million | Fiscal year 2024: $54.13 million | Fiscal year 2023: $81.60 million | Fiscal year 2022: $44.72 million | Fiscal year 2021: $80.13 million | Fiscal year 2020: $74.15 million | Fiscal year 2019: $68.42 million | Fiscal year 2018: $91.91 million | Fiscal year 2017: $9.08 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: